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Abstract
Infectious disease is an important problem for animal breeders, farmers and governments worldwide. One approach to
reducing disease is to breed for resistance. This linkage study used a Charolais-Holstein F2 cattle cross population (n=501)
which was genotyped for 165 microsatellite markers (covering all autosomes) to search for associations with phenotypes for
Bovine Respiratory Syncytial Virus (BRSV) specific total-IgG, IgG1 and IgG2 concentrations at several time-points pre- and
post-BRSV vaccination. Regions of the bovine genome which influenced the immune response induced by BRSV vaccination
were identified, as well as regions associated with the clearance of maternally derived BRSV specific antibodies. Significant
positive correlations were detected within traits across time, with negative correlations between the pre- and post-
vaccination time points. The whole genome scan identified 27 Quantitative Trait Loci (QTL) on 13 autosomes. Many QTL
were associated with the Thymus Helper 1 linked IgG2 response, especially at week 2 following vaccination. However the
most significant QTL, which reached 5% genome-wide significance, was on BTA 17 for IgG1, also 2 weeks following
vaccination. All animals had declining maternally derived BRSV specific antibodies prior to vaccination and the levels of
BRSV specific antibody prior to vaccination were found to be under polygenic control with several QTL detected. Heifers
from the same population (n=195) were subsequently immunised with a 40-mer Foot-and-Mouth Disease Virus peptide
(FMDV) in a previous publication. Several of these QTL associated with the FMDV traits had overlapping peak positions with
QTL in the current study, including the QTL on BTA23 which included the bovine Major Histocompatibility Complex (BoLA),
and QTL on BTA9 and BTA24, suggesting that the genes underlying these QTL may control responses to multiple antigens.
These results lay the groundwork for future investigations to identify the genes underlying the variation in clearance of
maternal antibody and response to vaccination.
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Introduction
Infectious disease in livestock is a cause for great concern for
both farmers and governments worldwide. Although many
countries maintain good animal husbandry, farm management
practices and vaccinate their livestock, failure in one or more of
these control measures allows infectious disease to prevail [1].
More effective vaccines and the ability to breed for resistance have
the potential to provide solutions for the control of both endemic
and emerging or re-emerging infectious disease.
An understanding of the underlying genetics that control
variation in immune responses and infectious disease outcomes
may lead to the selection of more resistant animals, as well as
identifying new strategies for improving vaccine efficacy. One
example where genetic selection for improved resistance has the
potential to make an impact is Bovine Respiratory Disease (BRD).
Bovine respiratory disease has a complex aetiology caused by
many different pathogens including viruses and bacteria [2–4] and
affects cattle world-wide, resulting in major welfare problems and
economic losses [5]. Both dairy and beef cattle show a wide range
of clinical signs related to BRD, including nasal discharge,
coughing, fever and decreased appetite when infected. There is
evidence that the genetic makeup of the host contributes to the
variation in BRD outcome although heritability estimates are low
[5–9]. However, this evidence comes from field studies where the
causal pathogen(s) were not identified, and thus the heritability of
response to particular infections may be underestimated.
Bovine Respiratory Syncytial Virus (BRSV) is the most common
viral pathogen implicated in outbreaks of BRD [10,11], with an
estimated 70% of calves in the UK becoming seropositive to the
virus by 1 year of age [10]. Genetic factors have been shown to
play a role in human susceptibility to the related pathogen,
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epidemiology and pathology of HRSV and BRSV are similar [11],
it is possible that at least a proportion of the genetic variation
associated with BRD outcome [9,13], may be related to the
genetically controlled response to BRSV infection [14]. However,
to date, no study of the genetic control of the response to a BRSV
infection has been conducted in cattle.
Although vaccination is generally considered to be a useful
means of controlling certain respiratory diseases in cattle
populations, neither natural infection nor vaccination induces
long lasting immunity [15] and young calves can be repeatedly
infected. From studies of rodent models and humans, it has been
suggested that a Th2 biased response may predispose the host to
higher levels of pathology, whereas a T helper (Th) 1 biased
response may be associated with protection [15]. Indeed, there are
no licensed HRSV vaccines for humans, because following
vaccination with a formalin-inactivated viral vaccine severe lung
pathology was caused by natural infection [15]. Similarly in cattle
there is evidence that an IgE Th2 biased response may be
associated with greater clinical signs in both naturally infected
calves and in response to formalin inactivated vaccines [16].
However, both modified live and inactivated viral vaccines are
available for BRSV and are considered to be safe for use in cattle
[14]. The efficacy of these vaccines is, however, low, especially in
younger animals, with immature immune systems [17]. A further
problem is that maternal antibody may also inhibit the induction
of protection induced by vaccination [18].
Immunity to BRSV is generally considered to require
neutralising antibody, but cellular immunity also plays an
important role. However, cellular immunity may also induce
pathology [19]. A fine balance between Th1 versus Th2 responses
may be critical in determining the outcome of both BRSV
vaccination and infection. In addition, an optimum level and
timing of each type of response may be required to ensure that
vaccines are protective and do not predispose to disease. The Th1
cytokine, interferon-c (IFNc) has been associated with protection
against BRSV pathology [20–22] as has the corresponding Th1
antibody isotype, IgG2 [20]. The Th2 associated antibody isotype,
IgG1, may be required for viral clearance and protection [23].
The production of IgE is generally considered to be part of a Th2
biased response, and has been associated with pathology in
relation to BRSV infection and formalin inactivated viral vaccines
[16]. However cytokines associated with both Th1 (IL-2 and
IFNc) and Th2 (IL-4) mediated responses were also up-regulated
during BRSV infection [24]. It therefore seems likely that
coordination of both Th1 and Th2 responses are required for
optimal protection and reduced pathogenesis in BRSV infections
in cattle.
In order to explore the factors underlying variation in the
response of cattle to BRSV, a large study was conducted using
young calves of a Charolais-Holstein cross population. A
significant proportion of the variation of IgG1 and IgG2 responses
to a live attenuated BRSV vaccine in these calves has been
attributed to genetic factors as shown by sire and breed effects
[25]. The clearance of maternal antibody to BRSV was also shown
to have a genetic component. More recently we have shown that
polymorphisms in one of the primary candidate loci implicated in
the control of immune responsiveness, the Major Histocompati-
bility Complex (MHC) DRB3 gene, accounts for a proportion of
the variation seen in response to the BRSV vaccine [26], however
most of the genetic variation was shown to be controlled by non-
MHC genes.
A long sought goal for animal breeders has been an ability to
improve resistance to many pathogens. However it is not clear if
this is a realizable goal. Identification of regions of the genome
controlling responses to multiple pathogens or vaccine compo-
nents may potentially make good targets for selective breeding and
identify new pathways for improving vaccine efficacy in general. A
previous immune-related Quantitative Trait Loci (QTL) study
[27], used a foot-and-mouth disease virus (FMDV) peptide to elicit
an immune response measured on the same animals as the current
study using the BRSV vaccination. Thus we have also investigated
if specific regions of the genome appear to control the response to
BRSV vaccination in addition to the FMDV peptide.
In this paper we report a linkage analysis with 165 microsatellite
markers to associate regions of the bovine genome with antibody
isotype responses to a BRSV vaccine and compare the results with
an earlier QTL study of response to a FMDV peptide carried out
in the same population. QTL that account for a significant
proportion of the variance in response to the BRSV vaccine were
discovered, several of which overlap with those found in the
FMDV study.
Results
A total of 468 second generation (245 male and 223 female)
animals of the RoBoGen Charolais6Holstein herd were pheno-
typed for total IgG, IgG1 and IgG2 responses to a BRSV vaccine
over time. The whole herd (984 animals) was genotyped with 165
microsatellite markers.
Essentially all of the parameters of all the traits in this study have
been previously described [25] (with exception of the addition of
weight to the REML models, which was not found to be
significant), but a summary table of the means, ranges and
standard deviations of the traits are presented here for clarity
(Table S1). Prior to vaccination, calves had declining levels of
circulating BRSV-specific antibody, which was most likely
maternally derived. After the initial vaccination, both IgG1 and
IgG2 levels increased. The observed increase at each subsequent
time point was significant (p,0.01) until a plateau was reached at
day 35 for IgG1 and at day 49 for IgG2 (IgG1=38.96 ROD,
IgG2=13.07 ROD. Table S1). Considerable variation in the
levels of IgG1 and IgG2 was apparent between animals at all time
points measured. However, the average IgG2 response remained
lower than the average IgG1 response throughout the time course
(Table S1).
Correlations between anti BRSV: total IgG, IgG1 and IgG2
All traits were analysed for possible correlations with each other
(pre vaccination correlations not shown) and many significant
correlations within specific traits were found over time (Table S2).
The IgG1 and IgG2 responses to BRSV vaccination at earlier time
points correlated with their next corresponding time points. Thus
the IgG1 level at week 2 correlated with the IgG1 level at week 5
(r
2=0.26, p,0.01) and the IgG1 level at week 5 correlated with
the IgG1 level at week 7 (r
2=0.69, p,0.01). Similar correlations
were found for the IgG2 levels. Furthermore, each time point
correlated with the AUC for each respective isotype level, with the
highest correlation found between the IgG2 week 5 post
vaccination and the IgG2 AUC measurement (r
2=0.79,
p,0.01). The two BRSV specific IgG isotype levels were also
significantly positively correlated with each other (Table S2). The
highest correlation was between IgG1 and IgG2 at week 7
(r
2=0.47, p,0.01). As expected, there were also negative
correlations between the levels of antibody at week 0 and levels
post-vaccination as the animals had pre-existing levels of IgG
derived from colostrum, which inhibited the vaccine response
[18,25].
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A total of 27 QTL for BRSV response were discovered across
13 autosomes, with 9 QTL found on the initial genome scan and 4
QTL discovered when background effects were taken it account
(Table 1). Seven QTL were above the 1% chromosome level, and
of these, one QTL on BTA 17 was at the 5% genome wide
significance level, explaining 3.47% of the phenotypic variance
(sp) (Fig. 1). The remaining 16 QTL were all above the 5%
chromosome wide significance level.
Of the 27 QTL detected, 16 were associated with the IgG2
response (mean sp accounted for 2.5%), whilst 7 QTL were
associated with the total IgG response (mean sp accounted for
2.3%) and only 4 with the IgG1 response (mean sp accounted for
2.6%). Thus loci accounting for a greater proportion of genetic
effects controlling the phenotypic variance of the IgG2 antibody
levels were identified in comparison to the total IgG and IgG1
antibody levels.
The traits in this study are linked (Total IgG is composed of
IgG1 and IgG2), thus as several QTL co-located (the QTL peaks
are within 20 cM of each other) it may be indicative that single
QTL at these positions controlled several traits at different time
points. If this is so, then there are 17 independent QTL (1 on
BTA2; 2 on BTA3; 2 on BTA7; 1 on BTA8, BTA9, BTA10,
BTA14 and BTA15; 2 on BTA17 and BTA18; 1 on BTA23,
BTA24 and BTA28).
Nearly all of the QTL (23) identified showed significant additive
effects (p,0.05), whereas only 7 showed significant dominant
effects (p,0.05). Both Holstein and Charolais derived alleles were
shown to have additive and/or dominance effects on QTL.
Fourteen of the 27 QTL with significant additive effects had the
Holstein derived alleles increasing the trait value (4 total IgG
QTL, 2 IgG1 QTL and 8 IgG2 QTL); whilst 10 had Charolais
derived alleles increasing the trait value (3 total IgG QTL, 1 IgG1
QTL and 6 IgG2 QTL) as shown in Table 1. Seven QTL had
Table 1. All QTL located in this study.
Chromosome
1 Trait
2 cM
3 F
4 a
5 d
5 Var%
6
95% C.I. of QTL
Position
7
2 Total_IgG_week_0 18 cM 5.47 23.67** 6.22** 2.11 6–124 cM
2 IgG2_minus_week_2 19 cM 6.25 24.22* 9.07** 2.67 60–124 cM
3 IgG2_minus_week_2 37 cM 5.19 1.89 6.77** 2.24 0–87 cM
3 IgG2_week_2 98 cM 4.88 1.03** 0.35 2.12 0–98 cM
7 IgG2_week_0 69 cM 5.21 0.74** 20.1083 2.26 5–98 cM
7 Total_IgG_week_2 22 cM 4.92 3.97* 24.8454 2.14 10–84 cM
8 IgG1_AUC 38 cM 5.9 26.36*** 23.34 2.52 6–118 cM
8 IgG1_week_7 44 cM 5.63 4.77*** 0.32 2.42 0–118 cM
8 Total_IgG_AUC 43 cM 4.98 25.80** 23.62 2.12 6–118 cM
8 Total_IgG_week_7 47 cM 5.53 5.63*** 0.7997 2.40 0–118 cM
9 IgG2_week_2 45 cM 5.47 20.87* 0.87 2.37 0–60 cM
10 IgG2_week_0 53 cM 7.01* 20.07 21.03*** 3.01 48–138 cM
14 IgG2_AUC 15 cM 6.82* 13.67*** 5.77 2.92 0–58.5 cM
14 IgG2_week_2 23 cM 5.79 0.99** 1.19* 2.51 6.5–60 cM
14 IgG2_week_7 16 cM 5.82 4.14*** 20.13 2.51 0–65.5 cM
15 Total_IgG_week_0 60 cM 4.85 3.64** 22.73 2.10 0–80 cM
17 IgG2_minus_week_2 15 cM 4.88 26.13 6.83 2.09 0–80 cM
17 IgG2_minus_week_2 57 cM 4.92 26.44** 3.51 2.10 0–80 cM
17 IgG1_week_2 76 cM 8.17** 24.30*** 1.99 3.47 28–80 cM
17 Total_IgG_week_2 76 cM 6.67* 24.20*** 1.51 2.87 28–81 cM
18 IgG2_week_2 19 cM 7.29* 23.58*** 22.20* 3.15 0–52 cM
18 IgG2_week_2 38 cM 5.81* 20.96** 20.90 2.52 18–52.5 cM
18 Total_IgG_week_7 18 cM 5.27 24.67** 21.83 2.28 0–67 cM
23 IgG2_AUC 27 cM 4.97 17.17** 1.71 2.15 0–80 cM
23 IgG2_week_2 31 cM 6.82* 2.03*** 0.36 2.86 0–63 cM
24 IgG2_week_2 11 cM 4.15 0.16 1.48** 1.81 0–49 cM
28 IgG1_week_7 0 cM 4.37 3.41* 0.64 1.89 0–34 cM
1Chromosome: the chromosome each QTL is located on.
2Trait: each trait is shown as follows: total IgG or IgG isotype response, followed by the week relative to vaccination.
3cM: the QTL position on the chromosome (centiMorgans).
4F: the F-statistic of each QTL, all are at least 5% chromosome wide, * 1% Chromosome wide and ** 5% Genome wide.
5‘‘a’’ and ‘‘d’’ are the additive and dominance effects of each QTL, *=p,5%, **=p,1% and ***=p,0.01%.
6Var%: the additive phenotypic variance explained by the QTL.
7The 95% confidence intervals of each QTL (centiMorgans).
doi:10.1371/journal.pone.0033526.t001
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effects with increases of the trait attributed to the Holstein alleles
(all IgG2 QTL), whilst 2 QTL were traceable to Charolais alleles
increasing the trait (Total IgG QTL and one IgG2 QTL). Overall,
there did not appear to be a breed bias towards additive or
dominance effects. However, the alleles derived from the Holstein
breed appeared to increase the immune traits more frequently
than the Charolais alleles in this study.
The QTL associated with total IgG levels tended to overlap (+/
2 7 cM of the peaks) with either IgG1 or IgG2 QTL. Five of the
seven total IgG QTL overlapped (BTA2, two on BTA8, BTA17
and BTA18; Table 1), reflecting the fact that the total IgG
phenotype was made up from the components of the IgG1 and
IgG2 phenotypes. These overlapping QTL also included an
overlap between QTL associated with total IgG AUC and the
IgG1 AUC on BTA 8 (Fig. 2).
A total of 8 QTL were associated with the IgG levels prior to
vaccination, whereas the majority of QTL were associated with
the response post vaccination and were mostly on different
chromosomes from those associated with the pre-vaccination levels
(Table 1). The trait with the greatest number of different QTL
associated with it was the IgG2 response 2 weeks post vaccination,
with a total of 7 QTL, in contrast to the single QTL associated
with the IgG1 response at the same time point. Fewer QTL were
Figure 1. BTA 17: Significant QTL. F-statistic profiles for the total IgG and IgG1 response elicited by the BRSV vaccine two weeks post vaccination.
The dashed horizontal line represents the threshold of the 1% chromosome wide significance level (F=6.26) and the constant horizontal line
represents the threshold of the 1% chromosomal wide significance level (F=8.16).
doi:10.1371/journal.pone.0033526.g001
Figure 2. BTA 8: Significant QTL. F-statistic profiles for the total IgG and IgG1 responses elicited by the BRSV vaccine seven weeks post
vaccination and using the AUC measurement. All the QTL are above the 5% chromosome wide significance level.
doi:10.1371/journal.pone.0033526.g002
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with only one associated with the IgG2 response at week 7, but two
for the IgG1 response at this time point.
The most significant QTL were mainly associated with the
IgG2 responses, with 5 of the 7 QTL above the 1% chromosome
significance level (including the QTL also at the 5% genome wide
significance level). These QTL also had other QTL within the
confidence intervals for differing traits and time points (with the
exception of the QTL located on BTA 10, Table 1). For example:
BTA 14 contains a QTL associated with the IgG2 AUC
measurement at the 1% chromosome wide significance level
(Fig. 3) and within 8 cM of the peak of this QTL are QTL for
IgG2 week 2 and IgG2 week 7 post vaccination. In addition,
another 2 QTL associated with the immune response post
vaccination (IgG2 week 2, 1% chromosome wide and the IgG2
AUC measurement, 5% chromosome wide) were discovered on
BTA 23, with their peaks separated by 5 cM (Fig. 4).
Fourteen of the QTL identified in this study were within the
confidence intervals of QTL detected in the FMDV study [27].
Furthermore, the peaks of four of these QTL were within 10 cM
of QTL peaks associated with the response to the FMDV peptide
and included BTA 9 at 45 cM, BTA23 at 27 cM and 31 cM and
BTA24 at11 cM. Of the overlapping QTL, the QTL on BTA 23
were the most striking, as two QTL from both studies overlapped
across the same regions of BTA23 (Fig. 4) which contains the
MHC region.
Discussion
In this study we have discovered a number of distinct QTL
which contribute to the control of the immune response to BRSV
vaccination as well as clearance of maternal antibody in cattle.
Although there was evidence for QTL within the MHC region on
BTA23, the majority of the QTL described in this paper do not lie
within this region. Our evidence suggests that some chromosomal
regions may control both the IgG1 and IgG2 response. However,
most of the QTL detected appear to play a role in the IgG2
response. This study is a follow on from our previous study of the
same crossbred herd which found strong heritability (h
2=0.52
with respect to total IgG levels over time (day0–day35)) and
significant sire effects in the IgG response post vaccination [25]. In
the present study 27 significant QTL were associated with BRSV
specific IgG1, IgG2 and total IgG levels, pre- and post-
vaccination, which were located on 13 bovine autosomes. The
multigenic nature of the response must at least in part, reflect the
complexity of host immunity.
In the previous study the Holstein backcross calves were shown
to exhibit significantly higher antibody levels than the Charolais
backcross calves pre-vaccination but not post-vaccination [25].
The QTL found in the current study did not reflect this, as both
breeds had similar QTL additive effects, although the Holstein
backcrosses generally had higher antibody levels pre-vaccination.
This finding is in contrast to a study which investigated bovine
keratoconjunctivitis [28], where the additive effects of QTL
originated from a breed with known low prevalence of the disease
[29]. This suggests that further QTL are yet to be discovered,
which may explain the higher antibody levels in the Holstein
backcross cattle pre-vaccination. Furthermore, most of the
significant dominance effects of QTL associated with pre-
vaccination levels, were derived from the Charolais breed,
suggesting a complex mode of inheritance may be responsible
for the observed phenotypes, such as parent-of-origin effects [30]
or over-dominance [31]. Further studies would be warranted to
investigate these dominance effects as breeding programs only
consider additive effects [32].
The persistence of circulating maternal antibodies has been
shown to have an effect on the efficacy of vaccination against
several important infectious diseases [33]. It is considered
preferable to vaccinate calves against BRSV at an early age,
because it is prevalent and can cause serious clinical disease, even
though maternal antibodies affect BRSV vaccine efficacy [34]. In
the present study the levels of anti-BRSV IgG were declining prior
to vaccination, a pattern most likely due to the clearance in the
levels of circulating maternal antibody [18,25]. Thus the process of
detecting QTL for antibody response post-vaccination may have
also been affected by the unknown effect of maternal antibody on
the efficiency of immunisation.
Eight QTL were detected associated with the BRSV-specific
antibody levels pre-vaccination. Two of these on chromosomes 10
Figure 3. BTA 14: Significant QTL. F-statistic profiles for the IgG2 response elicited by the BRSV vaccine two and seven weeks post vaccination
and using the AUC measurement. The constant horizontal line represents the threshold of the 1% chromosomal wide significance level (F=6.43).
doi:10.1371/journal.pone.0033526.g003
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while the others were on chromosomes with post-vaccination
QTL, but with apparently different peaks. These QTL may
therefore reflect genes/pathways which impact on the persistence
of maternal antibody. The transfer of IgG from dam to calf via
colostrum has high heritability [35]. The results presented here
suggest that IgG transfer may be partly controlled by the genetics
of the calf. Furthermore, the neonatal Fc receptor, a heterodimer
consisting of a MHC class I a-chain homolog located on BTA18
[36] and beta-2-microglobulin (b2m), located on chromosome 10
[37], may play a significant role in regulating the level of maternal
antibody [36]. Polymorphisms in the MHC a-chain homolog on
BTA 18 have been associated with the levels of IgG in newborn
calves [36]. However the QTL detected on BTA18 were
associated with the post-vaccination response and not pre-
vaccination levels. Furthermore, the gene for the MHC a-chain
homolog is located outside of the final marker on that
chromosome, and thus outside the confidence intervals for these
QTL; further genotyping in this region may be able to provide
better resolution. In addition, the gene encoding b2m, which has
been associated with the failure of transfer of maternal IgG to
calves [40] is positioned just outside of the confidence interval of
the pre-vaccination QTL located on BTA10 which was the only
QTL detected in the current study on this chromosome. Addition
of markers to the analysis of BTA 10 may better define the QTL
position and determine whether b2m is a putative candidate gene
controlling pre-immune IgG. Identifying the genes underlying the
QTL associated with variation in levels of maternal antibody could
potentially aid the design of future vaccines to minimise the
interference effects of maternal antibodies.
A single QTL was identified, located on BTA 14, which
influenced the response at different time points, which appears to
influence the IgG2 response at 2 and 7 weeks post vaccination as
well as the overall (AUC) IgG2 response post vaccination. This is
in marked contrast to the 8 clusters of QTL that were associated
with the response to the FMDV peptide over time [27]. However
more time points were measured in the FMDV study which may
have increased the chances of detecting QTL over time. Also the
FMDV antibody levels were measured with higher resolution and
were not influenced by maternal antibody, both of which may
have reduced the ability to detect BRSV related QTL in the
current study. No T cell response was detected post vaccination
(results not shown). Although it is clear that cell mediated
immunity is important for protection against BRSV [15], generally
peripheral blood BRSV-specific T cell responses to modified-live
vaccines are only detected in seronegative calves [38] or in
experimental vaccines formulated to potentiate cellular immunity
(e.g.[39] and [21]). Nonetheless the data indicate that distinct
genes operate early in the primary BRSV vaccine response
compared to those that underlie variation following the boost. The
QTL associated with the IgG2 response at week 2 following the
primary vaccination also accounted for the most phenotypic
variance. In addition, the IgG2 response at week 2 had the most
QTL associated to it within this study, which altogether explained
over 17% of the IgG2 response at this time point. As the responses
at later time points also correlate with the week 2 response, this
suggests that these QTL may be particularly important in
determining the overall IgG2 response. In contrast, no QTL were
identified which were associated with either IgG isotype, 5 weeks
post vaccination. Previously, it has been shown that the variation
in IgG1 and IgG2 at this time point is small among the different
second generation classes (F2 CB1 and HB1) [18]. Understanding
the genetic control of the variation in the IgG2 response
(associated with Th1 responses) at early time points, may suggest
new ways to modulate the Th1 and Th2 balance induced by
vaccination, which may be relevant for improved protection and
avoidance of adverse pathology following vaccination [15,16].
Markers associated with these genes would be valuable for
breeding for enhanced disease resistance.
In contrast to the response to the FMDV peptide [27], the anti
BRSV IgG1 and IgG2 levels were highly correlated, both pre and
post vaccination, however, no QTL for IgG1 levels were identified
that overlapped with QTL for IgG2 levels, which is in contrast to
the QTL for FMDV peptide response where three chromosomal
regions on BTA 20, 23 and 25 had QTL peaks for both anti-
FMDV peptide IgG1 and IgG2 responses [27]. These findings
imply strong correlation seen at the phenotypic level does not
necessarily indicate that the phenotypes share genetic control.
Thus although the levels of both antibody isotypes for BRSV
increased at similar rates post-vaccination, different genes may be
involved in controlling the response of IgG1 and IgG2. Although
cellular and humoral immunity play important roles in response to
BRSV, it remains unclear how the contribution of different isotype
subclasses of bovine immunoglobulin and components of cell
Figure 4. BTA 23: Significant QTL. F-statistic profiles for the IgG2 response elicited by the BRSV vaccine two weeks post vaccination (peak, 31; F-
statistic 6.82) and the AUC measurement (peak, 27; F-statistic, 4.97) and for the IgG1 (peak, 39; F-statistic, 4.16) and IgG2 (peak, 33; F-statistic, 4.08)
levels elicited by the FMDV peptide [27] 2 and 10 weeks post immunisation, respectively.
doi:10.1371/journal.pone.0033526.g004
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pathology in relation to BRSV [15]. Available evidence suggests
that a relative balance between Th1 and Th2 responses determine
the outcome of infection and vaccination, and that pathology can
be associated with an exacerbated Th2 response involving IgE
[16]. Our study design did not allow us to investigate protection
and pathology, and further studies are warranted to explore their
relationship with genetics of immune response. Nonetheless our
results suggest that host genetics may play a role in determining
the balance between Th1 and Th2 responses as well as explaining
a proportion of the considerable between animal variation.
Understanding the genes underlying regulation of Th1 and Th2
pathways could suggest new ways to immuno-modulate responses
to pathogens such as BRSV. Furthermore, the markers identified
here could be useful in marker assisted selection to select, for
example, animals with a lower Th2 response, thus potentially
reducing pathology when infected with BRSV.
Almost half of the 27 QTL significantly associated with IgG
levels pre and post BRSV vaccination, lie within the 95%
confidence intervals of the QTL associated with antibody
responses to the FMDV peptide [27]. Indeed, 10 of these QTL
are associated with the same IgG isotype, suggesting that the same
genes influence IgG levels post immunisation with different
immunogens. Furthermore, QTL identified in the current study
also fall within the confidence intervals of QTL associated with
other immune traits, including: the change of somatic cell score in
response to Mastitis [41] on BTA15; antibody response to
Mycobacterium avium ssp. paratuberculosis [42] on BTA 8 and 9; two
thirds of the haplotypes significantly associated with Bovine Viral
Diarrhea and eight SNP associated with BRD [43] on BTA2; and
bovine spongiform encephalopathy infection [44] on BTA 17.
This raises the possibility that the immune responses to different
stimuli may be controlled, to some degree, by similar pathways,
even if the initial detection of the infection occurs through distinct
mechanisms, downstream signalling may converge on similar
pathways. If the genes underlying these QTL are involved in
pathways that control responses to a wide range of pathogens they
may be suitable for selective breeding for disease resistance in
general. In addition, understanding of the underlying genes and
pathways could point to new targets for future immunomodulatory
substances such as adjuvants.
The MHC locus is expected to be a significant component
underlying variation in immune response [45], as it contains many
polymorphic and immune-related loci [46,47]. Indeed in both the
current study and the FMDV peptide study [27] QTL were
discovered that span the MHC locus. Indeed, earlier studies have
shown that polymorphisms at the DRB3 locus are associated with
response to BRSV [8,48] as well as protection against viral
challenge following immunisation with the FMDV peptide and
similar peptides [49]. However, the two QTL that span the MHC
loci that were identified in the present study only account for 3%
of the phenotypic variation, which together with previous data
from the FMDV study [27], indicates that many other regions of
the genome are involved in controlling variation in immune
responses.
The human strain of respiratory syncytial virus (HRSV), which
is closely related to BRSV, is a major cause of respiratory disease
in young children, where the epidemiology and pathogenesis of
infection is similar to that of BRSV [10]. The severity of disease in
young children caused by HRSV is significantly associated with
genes expressed during both innate and acquired immune
responses [50]. Eight of the twenty one genes implicated in the
human response to HRSV [50], have orthologs within the QTL in
the current study, on BTA 2, 3, 15, 17 and 23. These are STAT1
(BTA 2), TNF (BTA 23), VCAM1 (BTA 3) and IL15 (BTA17)
which play roles in innate immunity and CD28 (BTA 2), STAT1,
IL17 (BTA23) which play roles in adaptive immunity [51]. The
QTL with the highest significance in the current study (on BTA
17) encompassed IL17 within its 95% confidence intervals. Two
further genes, from the Janssen et al study [50], within these QTL
confidence intervals (MS4A2; FCER1A, both located on BTA 15)
are associated with asthma allergies as well as severe RSV disease.
It has also been suggested that a Th2 biased response in cattle,
associated with induction of IgE, is correlated with pulmonary
pathology in cattle [16], and thus polymorphisms in these genes
may also influence the pathology observed in young cattle infected
with BRSV. Further study on the role of genetic control of IgE
responses may also highlight these genes and others associated
with pathology. It is interesting to note that some of the SNPs
within IL15, STAT1, VCAM1 and TNF associated with HRSV in
the human study [50] are also polymorphic in the bovine genome,
making them very good candidates for further study
This is the first time that the natural variation in the clearance
of maternal antibody and the immune response to a BRSV
vaccine has been successfully exploited to locate significant QTL
in distinct regions of the bovine genome. A greater number of
QTL were found associated with IgG2 response and these
explained a larger part of the genetic variation than were found
for IgG1 response. Some of the QTL identified overlap with QTL
associated with the response to a FMDV peptide. Research is
ongoing to further reduce the QTL confidence intervals, with the
aim of identifying the underlying gene variants. This information
may be used to breed for disease resistance and the production of
more efficacious vaccines through the discovery of key genes and
gene pathways.
Materials and Methods
Ethics Statement
All animals were clinically normal and all experimental
protocols were authorised under the UK Animals (scientific
procedures) Act, 1986. In addition, The Roslin Institute’s Animal
Welfare and Ethics Committee (AWEC) ensure compliance with
all relevant legislation and promote the adoption and develop-
ments of the 3Rs (reduction, replacement, refinement).
Animals
A total of 501 cross-bred second generation animals were
produced in the RoBoGen herd. Pure-bred Charolais sires were
mated to Holstein dams to produce the F1 (137 animals) and 8 F1
sires were mated to F1 heifers to create the F2 (315 animals) of the
second generation. In addition the founder Charolais sires were
mated to F1 heifers to produce a Charolais backcross (CB1, 88
animals) and F1 sires were mated to pure bred Holstein heifers to
create a Holstein backcross (HB1, 98 animals). Thus the second
generation consisted of the F2, CB1 and HB1. The whole pedigree
consisted of 21 sires (8 F0, 13 F1) and 408 dams (131 F0, 277 F2).
All male calves had unrestricted suckling with their dams, at grass,
until approximately 4 months old. All female calves were weaned
by 36 h, segregated from the rest of the herd and raised indoors,
initially on milk-replacer then weaned early onto a propriety
compound diet. Any differences in the results observed between
sexes were therefore confounded by differences in management.
Vaccination with Rispoval and sampling
Immune response measurements were collected on 468 second
generation crossbred calves (294 F2, 90 HB1 and 81 CB1). The
age at first immunisation with the BRSV vaccine (Rispoval ,
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fell within the recommended vaccination period according to the
datasheet provided by the manufacturer. All animals were
vaccinated and IgG levels measured as described by O’Neill et al
[25]. Each animal received 2 ml of the attenuated live vaccine (the
vaccine contained no adjuvant), intramuscularly, according to the
manufacturer’s recommendations. All calves were re-immunized
with 2 ml of the vaccine intramuscularly, 3 weeks following the
initial vaccination. Blood samples were collected by jugular
venipuncture: 4 and 2 weeks pre-vaccination; at week 0 (the day
of first vaccination) and at 2, 5 and 7 weeks post-vaccination,
providing six samples per calf. Serum was collected within 2 h of
sampling and stored at 220uC until testing.
ELISA for detection of BRSV-specific total IgG, IgG1 and
IgG2
This assay was carried out as described in O’Neill et al, 2006
[25]. Briefly, sera were tested quantitatively by solid-phase
antibody capture ELISA specific for total BRSV-IgG according
to the manufacturer’s guidelines (Svanovir BRSV-Ab, Svanova
Biotech, Uppsala, Sweden). Samples were tested in duplicate, at a
dilution of 1/25 and optical densities (OD) read at 450 nm. The
corrected optical density value for each sample and the control
sera was calculated by subtraction of the OD value of each control
antigen-coated well from that of the corresponding viral antigen-
coated well and the relative optical density (ROD) value for each
sample was calculated as a proportion of a positive control serum
on a per-plate basis.
BRSV-IgG2 levels were tested using a modified form of the
above assay. All dilutions were as described above but 100 mlo f1 /
10,000 horse-radish peroxidase-conjugated anti-bovine IgG2
(Acris Antibodies GmBH, Hiddenhausen, Germany) was used as
the secondary antibody. The corresponding ROD values were also
calculated as above. To obtain the IgG1 levels, IgG2 was
subtracted from the total IgG, as described in O’Neill et al,
2006 [25].
Area under the curve (AUC) for each trait was also calculated
(using the trapezoidal rule [52]) to provide a single trait that
reflected the overall response of each animal.
Immunisation with the FMDV15 peptide
Full details of the FMDV peptide and the sampling protocols
have been previously published [27]. The peptide consisted of two
separate regions (residues 141 to 158 and 200 to 213) of the virus
coat protein (VP1) from the O1 Kaufbeuren strain of FMDV [53].
195 second generation cross heifers (121 F2, 43 HB1 and 31 CB1)
were immunised subcutaneously with 1 mg FMDV15 peptide/
animal emulsified in Freund’s incomplete adjuvant at week 0,
followed by a boost of 100 mg FMDV15 peptide/animal at week 6.
The age at initial immunisation with the peptide ranged from 469–
609 days. Thus the FMDV immunisation and collection of
phenotypes were done subsequently to the BRSV vaccination and
collection of phenotypes. Whole blood samples were collected by
jugular venipuncture from all of the female F2 and backcross
heifers, post immunisation at weeks 0, 1, 2, 4, 8 and 10 for IgG1
and IgG2 analysis. Animals used in the FMDV study were the
same female animals used in the BRSV study reported here.
For the IgG analysis, the blood samples were allowed to clot and
serum collected and stored at 220uC until they were tested.
FMDV15 peptide specific ELISAs were performed to measure
IgG1 and IgG2 isotypes as detailed in Baxter et al 2009 [25].
ELISAs were conducted within a short period following the final
sampling, to minimise technical variation.
Statistical Analysis – BRSV IgG
The IgG concentrations were log10 transformed to obtain a
normal distribution and constant variance, to permit REML
(REsidual Maximum Likelihood) analysis.
Significant factors, such as sire, within this study have been
previously calculated by O’Neill et al [25]. For the QTL
calculation, the final model included sire and dam as random
effects; the fixed effects within the model, with appropriate degrees
of freedom (df), were line (F2, CB1, HB1; 2d.f), age (age at
vaccination), cohort (1, 2, 3; 2d.f) and calculated weight (weight of the
animal at first vaccination date calculated from regression of
animal weight at other time points pre and post vaccination).
Thus the model was:
Yijk~mzLzCzSzb1:mzb2:azujzgkzeijk
Where: Yijk is the observed value of the phenotypic trait; m,
population mean; L, the fixed effect of line (F2, CB1 or HB1); C,
the fixed effect of cohort (3 Cohorts); S, the fixed effect of sex (male
or female); b1, the linear regression on the covariate of age at
vaccination, m (m=d469–d609); b2, the linear regression on the
covariate of weight, a (a=361–744 kg); uj, the random effect of
sire; gk, the random effect of dam g; eijk, the residual error
e,N(0,Is
2
p).
Correlations
The residuals, for each time point, from the Restricted
Maximum Likelihood (REML) models were saved and used to
calculate all the correlations between the immune responses at
differing time points throughout the study.
Genetic Markers
Standard phenol-chloroform methods were used to extract
DNA from blood samples [54]. A panel of microsatellite markers
were genotyped across all individuals in the herd, with a total of
165 microsatellite markers distributed across all 29 autosomes
[55]. All of the genotypes were stored in the ResSpecies database
[56] and used to build linkage maps with CRIMAP 2.4 [57]. The
maps were compared to a bovine linkage map [58]. Once
inconsistencies with the published linkage maps were resolved, the
maps constructed using CRIMAP were used to conduct putative
QTL analysis for the immune-related traits. The map is given in
Table S3.
QTL Analysis
GridQTL [59] an internet based software was used for the QTL
analysis, the F2 and backcross module was used which assumes
that founder lines are fixed for alternative alleles at QTL loci
(although they can be segregating at markers) and implements a
least squares analysis. Information content (IC) along the linkage
maps was also calculated by the program. Both single and two
QTL models with additive and dominance effects were fitted at
1 cM intervals along the autosomes, using a sex averaged genetic
map. By setting the two founder breeds as: breed 1=Holstein and
breed 2=Charolais, the positive or negative sign of the effects
(additive and dominance) dictated the origin of the allele (Holstein
or Charolais) which increased the trait value. Thus, when the
additive effect was positive, Holstein origins were responsible, and
when the additive effect was negative then Charolais origins were
responsible. However, when dominance effects shared the same
sign as the additive effects, Holstein origins were responsible, and
when the signs did not match, Charolais origins were responsible
for the increased phenotype.
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at weeks 4 and 2 pre-vaccination and 0, 2, 5, 7 post vaccination
along with AUC measurements) were tested for linkage association
using 165 microsatellite markers spread across all 29 autosomes in
the bovine genome. Significance thresholds were calculated by
permutation analysis with 2000 permutations [60]. Four signifi-
cance levels were used: chromosome-wide 5% and 1% and
genome-wide 5% and 1%.
Refining QTL
The QTL detected at the 5% chromosome-wide significance
level and above were included in the model and the genome
rescanned for further QTL. By adding the initial QTL as
background effects, the variance caused by them is removed, thus
potentially revealing previously undetectable QTL. In cases where
more than one QTL was found for the same trait on the same
chromosome, a 2 QTL model was applied by fitting two QTL
simultaneously and re-analysing the data. A forward and
backward selection interval mapping approach was used to check
whether QTL moved significantly [61]. These refining methods
were repeated, until no further QTL were detected. Finally,
bootstrap analysis was performed, using 2000 repeat samples, for
all chromosomes, where significant QTL were detected, to
estimate the 95% confidence intervals for the location of the
QTL [62].
Supporting Information
Table S1 Phenotype summaries. 1. Immunisation with
FMDV peptide (data from previous study [27]); BRSV vaccine
(data from previous study [25]). 2. Trait: each trait is shown as
follows: total IgG or IgG isotype response, followed by the week
relative to vaccination. 3. Mean: mean average of each time point.
BRSV specific antibody is measured as Relative Optical Density
whilst FMDV specific antibody is measured in ml/ml. 4. Range:
Minimum and maximum response for each time point (units as 3.).
5. SD: the standard deviation of each trait mean at each time
point.
(TIF)
Table S2 Correlations within and between the immune
responses to the BRSV vaccine. The x and y axes consist of
each week of the BRSV study [27]. Correlations are located below
the black shaded boxes. Above the black shaded boxes is the
significance of each correlation. The horizontal orange (IgG1
AUC measurement), green (IgG2 levels two post vaccination), red
(IgG2 levels 5 weeks post vaccination), blue (IgG2 levels 7 weeks
post vaccination) and purple (IgG2 AUC measurement) shaded
boxes represent the significant correlations throughout the BRSV
study. The vertical coloured shaded boxes highlight the corre-
sponding significance of the correlations.
(TIF)
Table S3 Linkage map. Marker distances (cM Kosambi) are
shown for the sex-average maps built for the Charolais6Holstein
population used in this study.
(TIF)
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